KR20160003115A - 제스트 인핸서 상동체 2 억제제 - Google Patents
제스트 인핸서 상동체 2 억제제 Download PDFInfo
- Publication number
- KR20160003115A KR20160003115A KR1020157033651A KR20157033651A KR20160003115A KR 20160003115 A KR20160003115 A KR 20160003115A KR 1020157033651 A KR1020157033651 A KR 1020157033651A KR 20157033651 A KR20157033651 A KR 20157033651A KR 20160003115 A KR20160003115 A KR 20160003115A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- methyl
- carboxamide
- cycloalkyl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CCN(C1CCOCC1)c1c[s]c(C(NCC2=C(C)C=C(C)NC2=O)=*)c1C Chemical compound CCN(C1CCOCC1)c1c[s]c(C(NCC2=C(C)C=C(C)NC2=O)=*)c1C 0.000 description 8
- AIIOKHOKGAEZOV-HFCKKAISSA-N CC(C)(C)OC(N[C@H](CC1)CC[C@@H]1/C(/c1c(C)c(C(OC)=O)c[s]1)=C\C)=O Chemical compound CC(C)(C)OC(N[C@H](CC1)CC[C@@H]1/C(/c1c(C)c(C(OC)=O)c[s]1)=C\C)=O AIIOKHOKGAEZOV-HFCKKAISSA-N 0.000 description 2
- PCJPGNCABBDNJU-UHFFFAOYSA-N CC(C=C(C)N1)=C(CN)C1=O Chemical compound CC(C=C(C)N1)=C(CN)C1=O PCJPGNCABBDNJU-UHFFFAOYSA-N 0.000 description 2
- KCDCTRRFNHNAFI-MRJYIUEKSA-N CCC([C@H](CC1)CC[C@@H]1NC(OC(C)(C)C)=O)c1c(C)c(C(OC)=O)c[s]1 Chemical compound CCC([C@H](CC1)CC[C@@H]1NC(OC(C)(C)C)=O)c1c(C)c(C(OC)=O)c[s]1 KCDCTRRFNHNAFI-MRJYIUEKSA-N 0.000 description 2
- YLVFAGSUDPEZEA-CPSFFCFKSA-N C/C=C(/CCCN1CCN(C)CC1)\c1c(C)c(C(O)=O)c[s]1 Chemical compound C/C=C(/CCCN1CCN(C)CC1)\c1c(C)c(C(O)=O)c[s]1 YLVFAGSUDPEZEA-CPSFFCFKSA-N 0.000 description 1
- HROLHLXMGDWYKN-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1[n]1ncc(-c2c(C)c(C(O)=O)c[s]2)c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1[n]1ncc(-c2c(C)c(C(O)=O)c[s]2)c1)=O HROLHLXMGDWYKN-UHFFFAOYSA-N 0.000 description 1
- IWFUYTDGNXGZMQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1[n]1ncc(-c2c(C)c(C(OC)=O)c[s]2)c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1[n]1ncc(-c2c(C)c(C(OC)=O)c[s]2)c1)=O IWFUYTDGNXGZMQ-UHFFFAOYSA-N 0.000 description 1
- ZOZZQJIESSTKJX-OIOUFDJBSA-N CC(C)(C)OC(N[C@H](CC1)CC[C@@H]1/C(/c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)=C\C)=O Chemical compound CC(C)(C)OC(N[C@H](CC1)CC[C@@H]1/C(/c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)=C\C)=O ZOZZQJIESSTKJX-OIOUFDJBSA-N 0.000 description 1
- HREMAGBXPZHMJC-UHFFFAOYSA-N CC(CCC1)N1c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 Chemical compound CC(CCC1)N1c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 HREMAGBXPZHMJC-UHFFFAOYSA-N 0.000 description 1
- SAPSRQJMZHFDOW-UHFFFAOYSA-N CC(NC1=O)=CC(Cl)=C1C#N Chemical compound CC(NC1=O)=CC(Cl)=C1C#N SAPSRQJMZHFDOW-UHFFFAOYSA-N 0.000 description 1
- WMPRWVSFHGPPNE-UHFFFAOYSA-N CC(NC1=O)=CC(O)=C1C#N Chemical compound CC(NC1=O)=CC(O)=C1C#N WMPRWVSFHGPPNE-UHFFFAOYSA-N 0.000 description 1
- ZDIWSICUBDWNBI-UHFFFAOYSA-N CC(c1c(C)c(C(OC)=O)c[s]1)=O Chemical compound CC(c1c(C)c(C(OC)=O)c[s]1)=O ZDIWSICUBDWNBI-UHFFFAOYSA-N 0.000 description 1
- CHYKQJNGGRRADW-UHFFFAOYSA-N CC(c1c(C)c(C(OC)=O)c[s]1)O Chemical compound CC(c1c(C)c(C(OC)=O)c[s]1)O CHYKQJNGGRRADW-UHFFFAOYSA-N 0.000 description 1
- XCCDOHKTQIGIQF-UHFFFAOYSA-N CC1(C)OB(c2c(C)c(C(OC)=O)c[s]2)OC1(C)C Chemical compound CC1(C)OB(c2c(C)c(C(OC)=O)c[s]2)OC1(C)C XCCDOHKTQIGIQF-UHFFFAOYSA-N 0.000 description 1
- HXOSRBBMCNHVHF-UHFFFAOYSA-N CCC(C)C(C(CCN(C1)C(OC(C)(C)C)=O)C1F)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 Chemical compound CCC(C)C(C(CCN(C1)C(OC(C)(C)C)=O)C1F)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 HXOSRBBMCNHVHF-UHFFFAOYSA-N 0.000 description 1
- QWQOUCCBLMVBJR-YGQOYYDZSA-N CCC([C@H](CC1)CC[C@@H]1NC(OC(C)(C)C)=O)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 Chemical compound CCC([C@H](CC1)CC[C@@H]1NC(OC(C)(C)C)=O)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 QWQOUCCBLMVBJR-YGQOYYDZSA-N 0.000 description 1
- OBWHFTGGXGNDQX-UHFFFAOYSA-N CCC(c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)=C1CCNCC1 Chemical compound CCC(c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)=C1CCNCC1 OBWHFTGGXGNDQX-UHFFFAOYSA-N 0.000 description 1
- LVGCTQDARMZPSW-UHFFFAOYSA-N CCC(c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)N(CC1)CCC1N(C)C Chemical compound CCC(c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)N(CC1)CCC1N(C)C LVGCTQDARMZPSW-UHFFFAOYSA-N 0.000 description 1
- ZJLVOCSRTYKWRM-WDZFZDKYSA-N CCCC/C(/c1c(C)c(C(OC)=O)c[s]1)=C/C Chemical compound CCCC/C(/c1c(C)c(C(OC)=O)c[s]1)=C/C ZJLVOCSRTYKWRM-WDZFZDKYSA-N 0.000 description 1
- CSCSQDXFHIMCOA-UHFFFAOYSA-N CCN(C(CCN(C1)C(OC(C)(C)C)=O)C1F)c1c(C)c(C(O)=O)c[s]1 Chemical compound CCN(C(CCN(C1)C(OC(C)(C)C)=O)C1F)c1c(C)c(C(O)=O)c[s]1 CSCSQDXFHIMCOA-UHFFFAOYSA-N 0.000 description 1
- FZYCWJYPPHUYEK-UHFFFAOYSA-N CCN(C(CCNC1)C1F)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 Chemical compound CCN(C(CCNC1)C1F)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1 FZYCWJYPPHUYEK-UHFFFAOYSA-N 0.000 description 1
- SBXDDBKIMZNNKE-SHTZXODSSA-N CCN(C)[C@H](CC1)CC[C@@H]1N(CC)c1c(C)c(C(CO)=O)c[s]1 Chemical compound CCN(C)[C@H](CC1)CC[C@@H]1N(CC)c1c(C)c(C(CO)=O)c[s]1 SBXDDBKIMZNNKE-SHTZXODSSA-N 0.000 description 1
- CJIZFOICFTVTGK-UHFFFAOYSA-N CCN(C1CCCCC1)c1c(C)c(C(OC)=[U])c(C#N)[s]1 Chemical compound CCN(C1CCCCC1)c1c(C)c(C(OC)=[U])c(C#N)[s]1 CJIZFOICFTVTGK-UHFFFAOYSA-N 0.000 description 1
- DLGUGHVRKSRQGE-UHFFFAOYSA-N CCN(C1CCOCC1)c([s]1)c(C)c(C(O)=O)c1Cl Chemical compound CCN(C1CCOCC1)c([s]1)c(C)c(C(O)=O)c1Cl DLGUGHVRKSRQGE-UHFFFAOYSA-N 0.000 description 1
- IESJTEZXBWQDBI-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)n[n]1C Chemical compound CCN(C1CCOCC1)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)n[n]1C IESJTEZXBWQDBI-UHFFFAOYSA-N 0.000 description 1
- ZOVDMQIGZGEXDX-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(O)=O)c(C)[s]1 Chemical compound CCN(C1CCOCC1)c1c(C)c(C(O)=O)c(C)[s]1 ZOVDMQIGZGEXDX-UHFFFAOYSA-N 0.000 description 1
- WAUYOOANGDXOEM-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(OC)=O)c(C)[s]1 Chemical compound CCN(C1CCOCC1)c1c(C)c(C(OC)=O)c(C)[s]1 WAUYOOANGDXOEM-UHFFFAOYSA-N 0.000 description 1
- QHNQZPFKGBKHQM-UHFFFAOYSA-N CCN(CC)c1c(C)c(C(OC)=O)c[s]1 Chemical compound CCN(CC)c1c(C)c(C(OC)=O)c[s]1 QHNQZPFKGBKHQM-UHFFFAOYSA-N 0.000 description 1
- ZSCQVKGNHJVDAL-DNLFPKPLSA-N CCN([C@H](CC1)CC[C@@H]1C(C)CC(OC(C)(C)C)=O)c1c(C)c(C(OC)=O)c[s]1 Chemical compound CCN([C@H](CC1)CC[C@@H]1C(C)CC(OC(C)(C)C)=O)c1c(C)c(C(OC)=O)c[s]1 ZSCQVKGNHJVDAL-DNLFPKPLSA-N 0.000 description 1
- NEGOYFGGWMLPMB-UHFFFAOYSA-N Cc([n](CC1CCOCC1)nc1)c1C(NCC1=C(C)C=C(C)NC1=O)=O Chemical compound Cc([n](CC1CCOCC1)nc1)c1C(NCC1=C(C)C=C(C)NC1=O)=O NEGOYFGGWMLPMB-UHFFFAOYSA-N 0.000 description 1
- MBNIQASQLNRJAV-UHFFFAOYSA-N Cc(c(C(OC)=O)c[s]1)c1I Chemical compound Cc(c(C(OC)=O)c[s]1)c1I MBNIQASQLNRJAV-UHFFFAOYSA-N 0.000 description 1
- IDHWXXAKXBPVRT-UHFFFAOYSA-N Cc1c(C(CCN)=O)[nH]cc1C(OC)=O Chemical compound Cc1c(C(CCN)=O)[nH]cc1C(OC)=O IDHWXXAKXBPVRT-UHFFFAOYSA-N 0.000 description 1
- QDPUOXFZEKRPQG-UHFFFAOYSA-N Cc1c(C)[s]c(Br)c1C(OC)=O Chemical compound Cc1c(C)[s]c(Br)c1C(OC)=O QDPUOXFZEKRPQG-UHFFFAOYSA-N 0.000 description 1
- FCKSGPKSSPUXOP-UHFFFAOYSA-N Cc1c[s]cc1C(OC)=O Chemical compound Cc1c[s]cc1C(OC)=O FCKSGPKSSPUXOP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361817436P | 2013-04-30 | 2013-04-30 | |
| US61/817,436 | 2013-04-30 | ||
| US201361842038P | 2013-07-02 | 2013-07-02 | |
| US61/842,038 | 2013-07-02 | ||
| US201361907024P | 2013-11-21 | 2013-11-21 | |
| US61/907,024 | 2013-11-21 | ||
| US201461936460P | 2014-02-06 | 2014-02-06 | |
| US61/936,460 | 2014-02-06 | ||
| PCT/IB2014/061012 WO2014177982A1 (en) | 2013-04-30 | 2014-04-25 | Enhancer of zeste homolog 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160003115A true KR20160003115A (ko) | 2016-01-08 |
Family
ID=50877537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157033651A Ceased KR20160003115A (ko) | 2013-04-30 | 2014-04-25 | 제스트 인핸서 상동체 2 억제제 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9505745B2 (enExample) |
| EP (1) | EP2991980B1 (enExample) |
| JP (1) | JP6373973B2 (enExample) |
| KR (1) | KR20160003115A (enExample) |
| CN (1) | CN105308038B (enExample) |
| AU (1) | AU2014261075B2 (enExample) |
| BR (1) | BR112015027527A2 (enExample) |
| CA (1) | CA2910873A1 (enExample) |
| CL (1) | CL2015003200A1 (enExample) |
| DO (1) | DOP2015000270A (enExample) |
| EA (1) | EA030196B1 (enExample) |
| ES (1) | ES2717680T3 (enExample) |
| HK (1) | HK1214815A1 (enExample) |
| MX (1) | MX2015015144A (enExample) |
| NZ (1) | NZ630205A (enExample) |
| PE (1) | PE20151981A1 (enExample) |
| PH (1) | PH12015502414A1 (enExample) |
| SG (1) | SG11201508203TA (enExample) |
| WO (1) | WO2014177982A1 (enExample) |
| ZA (1) | ZA201507398B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5989805B2 (ja) * | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| WO2014177982A1 (en) * | 2013-04-30 | 2014-11-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| AU2014288839B2 (en) | 2013-07-10 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of Zeste Homolog 2 inhibitors |
| SG11201606269WA (en) | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
| BR112017008840A2 (pt) * | 2014-10-28 | 2017-12-19 | Glaxosmithkline Ip No 2 Ltd | intensificador de inibidores do homólogo 2 de zeste |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| KR20180042356A (ko) | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| TW201718598A (zh) * | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2017079757A1 (en) * | 2015-11-06 | 2017-05-11 | Epizyme, Inc. | Pediatric dosing for treatment of cancer with an ezh2 inhibitor |
| RS59763B1 (sr) | 2015-11-19 | 2020-02-28 | Jiangsu Hengrui Medicine Co | Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini |
| KR20190003699A (ko) * | 2016-05-05 | 2019-01-09 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
| US20170337814A1 (en) * | 2016-05-20 | 2017-11-23 | Donald Edward Morgan | Safety alerting drivers device and system |
| KR102351782B1 (ko) | 2016-09-07 | 2022-01-17 | 상하이 하이헤 파마수티컬 컴퍼니 리미티드 | 피리도 5원 방향족 고리계 화합물, 이의 제조 방법 및 용도 |
| WO2018125983A1 (en) | 2016-12-30 | 2018-07-05 | Mitobridge, Inc. | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| MX2020007974A (es) | 2018-01-31 | 2020-09-07 | Mirati Therapeutics Inc | Inhibidores de complejo represivo polycomb 2 (prc2). |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| CN113544130B (zh) * | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| EP3980422A1 (en) | 2019-06-05 | 2022-04-13 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| CN110964200A (zh) * | 2019-12-19 | 2020-04-07 | 新纳奇材料科技江苏有限公司 | 一种基于聚硅氧烷馏出物的羟基封端聚硅氧烷的制备方法 |
| WO2021129629A1 (zh) * | 2019-12-23 | 2021-07-01 | 四川海思科制药有限公司 | Zeste增强子同源物2抑制剂及其用途 |
| CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
| US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007519753A (ja) * | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
| WO2005095386A1 (en) * | 2004-03-30 | 2005-10-13 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| JP5763636B2 (ja) * | 2009-08-07 | 2015-08-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規なアザ複素環化合物 |
| WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| JP5864546B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| EA023788B1 (ru) * | 2010-05-07 | 2016-07-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Производные индола и фармацевтические композиции на их основе |
| EP2646020B1 (en) | 2010-12-01 | 2016-09-21 | Glaxosmithkline LLC | Indoles |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| CA2850570A1 (en) | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| US9394283B2 (en) | 2012-04-13 | 2016-07-19 | Epizyme, Inc. | Salt form of a human histone methyltransferase EZH2 inhibitor |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| WO2014177982A1 (en) * | 2013-04-30 | 2014-11-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
-
2014
- 2014-04-25 WO PCT/IB2014/061012 patent/WO2014177982A1/en not_active Ceased
- 2014-04-25 KR KR1020157033651A patent/KR20160003115A/ko not_active Ceased
- 2014-04-25 SG SG11201508203TA patent/SG11201508203TA/en unknown
- 2014-04-25 PE PE2015002298A patent/PE20151981A1/es not_active Application Discontinuation
- 2014-04-25 JP JP2016511152A patent/JP6373973B2/ja not_active Expired - Fee Related
- 2014-04-25 EP EP14727619.0A patent/EP2991980B1/en active Active
- 2014-04-25 HK HK16102708.1A patent/HK1214815A1/zh unknown
- 2014-04-25 MX MX2015015144A patent/MX2015015144A/es unknown
- 2014-04-25 NZ NZ630205A patent/NZ630205A/en not_active IP Right Cessation
- 2014-04-25 CN CN201480033093.6A patent/CN105308038B/zh not_active Expired - Fee Related
- 2014-04-25 ES ES14727619T patent/ES2717680T3/es active Active
- 2014-04-25 EA EA201592068A patent/EA030196B1/ru not_active IP Right Cessation
- 2014-04-25 AU AU2014261075A patent/AU2014261075B2/en not_active Ceased
- 2014-04-25 CA CA2910873A patent/CA2910873A1/en not_active Abandoned
- 2014-04-25 BR BR112015027527A patent/BR112015027527A2/pt not_active IP Right Cessation
- 2014-04-25 US US14/787,866 patent/US9505745B2/en not_active Expired - Fee Related
-
2015
- 2015-10-06 ZA ZA2015/07398A patent/ZA201507398B/en unknown
- 2015-10-19 PH PH12015502414A patent/PH12015502414A1/en unknown
- 2015-10-30 CL CL2015003200A patent/CL2015003200A1/es unknown
- 2015-10-30 DO DO2015000270A patent/DOP2015000270A/es unknown
-
2016
- 2016-10-13 US US15/292,200 patent/US9790212B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PE20151981A1 (es) | 2016-01-14 |
| EP2991980A1 (en) | 2016-03-09 |
| NZ630205A (en) | 2017-03-31 |
| HK1214815A1 (zh) | 2016-08-05 |
| WO2014177982A1 (en) | 2014-11-06 |
| JP2016517878A (ja) | 2016-06-20 |
| CL2015003200A1 (es) | 2016-04-22 |
| AU2014261075B2 (en) | 2017-01-19 |
| BR112015027527A2 (pt) | 2017-07-25 |
| ES2717680T3 (es) | 2019-06-24 |
| CA2910873A1 (en) | 2014-11-06 |
| CN105308038B (zh) | 2018-05-29 |
| DOP2015000270A (es) | 2016-02-15 |
| CN105308038A (zh) | 2016-02-03 |
| AU2014261075A1 (en) | 2015-11-05 |
| EP2991980B1 (en) | 2019-01-02 |
| US20170029412A1 (en) | 2017-02-02 |
| ZA201507398B (en) | 2017-01-25 |
| MX2015015144A (es) | 2016-02-18 |
| US9790212B2 (en) | 2017-10-17 |
| US9505745B2 (en) | 2016-11-29 |
| PH12015502414A1 (en) | 2016-02-22 |
| US20160102083A1 (en) | 2016-04-14 |
| EA030196B1 (ru) | 2018-07-31 |
| JP6373973B2 (ja) | 2018-08-15 |
| SG11201508203TA (en) | 2015-11-27 |
| EA201592068A1 (ru) | 2016-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20160003115A (ko) | 제스트 인핸서 상동체 2 억제제 | |
| JP5864546B2 (ja) | インダゾール | |
| JP5864545B2 (ja) | インドール | |
| JP5889875B2 (ja) | アザインダゾール | |
| ES2607064T3 (es) | Indoles | |
| KR20150095779A (ko) | 제스트 인핸서 상동체 2 억제제 | |
| JP6571180B2 (ja) | Ｚｅｓｔｅホモログ２エンハンサー阻害剤 | |
| KR20160030221A (ko) | 제스트 인핸서 상동체 2 억제제 | |
| KR20160018594A (ko) | 제스트 인핸서 상동체 2 억제제 | |
| KR20160122266A (ko) | 제스트 인핸서 상동체 2 억제제 | |
| KR20180022834A (ko) | 제스트 인핸서 상동체 2 억제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20151125 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190419 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210219 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20210503 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20210219 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |